150019-57-1

Basic information

• Product Name: 4-Benzo[1,3]dioxol-5-yl-4-hydroxycyclohexanone
• Synonyms: 4-Benzo[1,3]dioxol-5-yl-4-hydroxycyclohexanone;4-Benzo[1,3]dioxol-5-yl-4-hydroxy-cyclohexanone;Cyclohexanone, 4-(1,3-benzodioxol-5-yl)-4-hydroxy-;4-(1,3-benzodioxol-5-yl)-4-hydroxycyclohexanone;4-(Benzo[d][1,3]dioxol-5-yl)-4-hydroxycyclohexanone
• CAS NO: 150019-57-1
• Molecular Formula: C₁₃H₁₄O₄
• Molecular Weight: 234.25
• Mol File: 150019-57-1.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 414.2 °C at 760 mmHg
• Flash Point: 162 °C
• Appearance: /
• Density: 1.348 g/cm³
• Vapor Pressure: 1.33E-07mmHg at 25°C
• Refractive Index: 1.605
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-Benzo[1,3]dioxol-5-yl-4-hydroxycyclohexanone(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Benzo[1,3]dioxol-5-yl-4-hydroxycyclohexanone(150019-57-1)
• EPA Substance Registry System: 4-Benzo[1,3]dioxol-5-yl-4-hydroxycyclohexanone(150019-57-1)

Safety Data

• Hazardous Substances Data: 150019-57-1(Hazardous Substances Data)

Usage

General Description

4-Benzo[1,3]dioxol-5-yl-4-hydroxycyclohexanone is a chemical compound with the molecular formula C13H12O4. It is a cyclic ketone containing a benzodioxole ring and a hydroxyl group attached to a cyclohexane ring. 4-Benzo[1,3]dioxol-5-yl-4-hydroxycyclohexanone is commonly used in organic synthesis and pharmaceutical research due to its potential therapeutic applications. It exhibits significant biological activities, including anti-inflammatory, analgesic, and antipyretic properties. Its unique molecular structure and functional groups make it a valuable intermediate in the synthesis of various pharmaceuticals and agrochemicals. Additionally, it is a useful building block in the production of natural products and other complex organic compounds.

InChI:InChI=1/C13H14O4/c14-10-3-5-13(15,6-4-10)9-1-2-11-12(7-9)17-8-16-11/h1-2,7,15H,3-6,8H2

Upstream product

• 17680-04-5 (3,4-methylenedioxy)phenylmagnesium bromide 
• 637-88-7 1,4-Cyclohexanedione 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 150019-56-0 8-(1,3-benzodioxol-5-yl)-1,4-dioxaspiro[4.5]decan-8-ol 

Downstream Products

• 150019-58-2 Cis phenylmethyl-4-[4-(1,3-benzodioxol-5-yl)-4-hydroxy-1-cyclohexyl]-1-piperazine carboxylate 
• 1262238-11-8 N-(2-{1-[4-(benzo[d][1,3]dioxol-5-yl)-4-hydroxycyclohexyl]-4-ethoxypyrrolidin-3-ylamino}-2-oxoethyl)-3-(trifluoromethyl)benzamide 
• 1262238-11-8 N-(2-{1-[4-(benzo[d][1,3]dioxol-5-yl)-4-hydroxycyclohexyl]-4-ethoxypyrrolidin-3-ylamino}-2-oxoethyl)-3-(trifluoromethyl)benzamide 

Relevant articles and documents

CHEMOKING RECEPTOR ANTAGONISTS

Disclosed herein are chemokine receptor antagonists of formula (I) wherein G1, X1, X2, and X3 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.

4-AZETIDINYL-1-PHENYL-CYCLOHEXANE ANTAGONISTS OF CCR2

The present invention comprises compounds of Formula (I): wherein: X, R1, R2, R3, and R4 are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

Development of a presynaptic 5-HT1A antagonist.

A new 5-HT(1A) silent antagonist 14 (5-HT(1A) IC(50)=2.2 nM) antagonizes the effects of agonists on reciprocal forepaw treading behavior, on neuronal firing in the rat dorsal raphe, and on 5-HT(1A) release in the raphe and hippocampus. While 14 alone was inactive in the social interaction paradigm, it completely reversed the social interaction activity of the serotonergic compounds (buspirone, 1, and 2).